PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
Open Access
- 3 October 2017
- journal article
- research article
- Published by Springer Nature in Diagnostic Pathology
- Vol. 12 (1) , 1-8
Abstract
Immune checkpoint blockade targeting PD-1/PD-L1 has shown efficacy in several types of cancers. However, the correlation between PD-L1/PD-1 expression and the specific clinicopathological features in papillary thyroid carcinoma (PTC) has not been investigated. We examined the immunohistochemical expression of PD-L1, PD-1, and BRAF V600E on whole-tissue sections from 126 cases of primary PTC more than 1 cm in size. The correlation between the PD-L1/PD-1 expression and the clinicopathological features was evaluated. PD-L1 was positively expressed in 53.2% PTCs, and its expression was positively correlated with rich tumor-infiltrating lymphocytes (TILs), background chronic lymphocytic thyroiditis (CLT), female gender, absence of psammoma bodies, and PD-1 expression. Among these parameters, rich TILs, female gender, and absence of psammoma bodies were independent factors affecting PD-L1 expression on the multivariate logistic regression analysis. PD-1 expression was detected in the TILs and was positively correlated with rich TILs, background CLT, and absence of stromal calcification. Lack of stromal calcification was an independent factor affecting PD-1 expression. Neither PD-L1 nor PD-1 expression showed significant correlation with BRAF V600E expression. Our results show that the distinctive pathological features of PTCs, including TILs, background CLT, female gender, psammoma bodies, and stromal calcification, are useful parameters for predicting PD-L1 or PD-1 expression.Keywords
Funding Information
- the National Nature Science Foundation of China (81202114)
- the National Nature Science Foundation of China (81301879)
- The Scientific Research Foundation for Returned Scholars, Ministry of Education of China
This publication has 34 references indexed in Scilit:
- Comprehensive screening for PD-L1 expression in thyroid cancerEndocrine-Related Cancer, 2017
- The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysisOncotarget, 2016
- Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variantsOncotarget, 2016
- BRAF Immunohistochemistry Using Clone VE1 is Strongly Concordant with BRAFV600E Mutation Test in Papillary Thyroid CarcinomaEndocrine Pathology, 2015
- Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid CancerJournal of Clinical Oncology, 2015
- Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1Pathology International, 2014
- Integrated Genomic Characterization of Papillary Thyroid CarcinomaCell, 2014
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014Annals of Oncology, 2014
- Clinical Utility of Thyroglobulin Antibody (TgAb) Measurements for Patients with Differentiated Thyroid Cancers (DTC)The Journal of Clinical Endocrinology & Metabolism, 2011
- The Association Between Chronic Lymphocytic Thyroiditis and Thyroid TumorsInternational Journal of Surgical Pathology, 2002